Compositions and methods for detecting human Pegivirus 2 (HPgV-2)

Patent metadata

Field	Value
Publication number	US-9777340-B2
Application number	US-201514752262-A
Country	US
Kind code	B2
Filing date	Jun 26, 2015
Priority date	Jun 27, 2014
Publication date	Oct 3, 2017
Grant date	Oct 3, 2017

Abstract

Provided herein are compositions, methods, and kits for detecting human Pegivirus 2 (HPgV-2). In certain embodiments, provided herein are HPgV-2 specific nucleic acid probes and primers, and methods for detecting HPgV-2 nucleic acid. In other embodiments, provided herein are HPgV-2 immunogenic composition compositions, methods of treating a subject with immunogenic HPgV-2 peptides, and methods of detecting HPgV-2 subject antibodies in a sample.

First claim

We claim:

1. A method of detecting human Pegivirus 2 (HPgV-2) specific antibodies in a subject comprising:
a) contacting a sample from a subject suspected of containing an antibody to HPgV-2 with a HPgV-2 peptide, wherein said peptide specifically binds said antibody to form a complex, and
wherein said HPgV-2 peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:86-99 and 100-218; and
b) detecting whether said antibody is present in said sample by detecting binding between said antibody and said peptide.

2. The method of claim 1 , wherein said amino acid sequence is selected from the group consisting of SEQ ID NOs: 129-132.

3. The method of claim 1 , wherein said amino acid sequence is selected from the group consisting of SEQ ID NOs: 163-166.

4. The method of claim 1 , wherein said amino acid sequence is selected from the group consisting of SEQ ID NOs: 209-212.

5. The method of claim 1 , wherein said amino acid sequence is selected from the group consisting of SEQ ID NOs: 213-218.

6. The method of claim 1 , where said amino acid sequence is selected from the group consisting of SEQ ID NOs: 209-218.

7. The method of claim 1 , wherein said HPgV-2 peptide comprises a label.

8. The method of claim 7 , further comprising contacting said sample with a solid support comprising moieties that bind said label.

9. The method of claim 8 , further comprising incubating said sample under conditions such that: i) said HPgV-2 peptide specifically binds said antibody to form a complex, and ii) said complex binds to said solid support via said label binding at least one of said moieties.

10. The method of claim 9 , further comprising washing said solid support.

11. The method of claim 10 , further comprising adding to said sample a detectably labeled secondary antibody capable of binding the antibody in said complex.

Assignees

• Abbott Lab
• Univ California

Inventors

• Chiu Charles
• Lee Deanna
• Berg Michael
• Dawson George
• Coller Kelly
• Cheng Kevin
• Hackett John
• Frankel Matthew
• Forberg Kenn

Classifications

• A61P31/14

  for RNA viruses · CPC title

• C12N2770/24034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2770/24021

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• A61K49/085

  conjugated systems · CPC title

• A61K39/12

  Viral antigens · CPC title